Beyond the Supplier: Building True Oversight in Contract Manufacturing

As medical device companies expand globally, their reliance on contract manufacturing organizations (CMOs) has accelerated. These partnerships help boost capacity, manage costs, and bring products to market faster. Along with these advantages, however, come complex challenges such as maintaining product quality, ensuring regulatory compliance, and safeguarding supply reliability across diverse external sites.

The success of any contract manufacturing strategy depends on one critical element—a strong and well-defined oversight organization. Building this capability requires more than assigning a few quality or supplier managers. It requires a deliberate framework, one that clarifies the business model, establishes effective governance, embeds robust quality systems, and cultivates transparent, trust-based relationships with CMOs.

This article outlines a practical approach to building such an oversight organization.

Why Oversight Matters

As medical device companies expand their use of contract manufacturing, the need for structured oversight grows. While production may occur externally, the sponsor organization retains ultimate responsibility for product quality, regulatory compliance, and patient safety under 21 CFR 820. Without effective oversight, a company is essentially at the mercy of the contract manufacturer, exposed to the decisions that diverge from the sponsor’s standards, creating long-term risks.

For example, a contract manufacturer acquired a mold from a lower-cost supplier without prior approval or defined equipment sourcing criteria. Unclear expectations resulted in poor-quality parts, added controls, increased cost, and delay. A stronger oversight model involving subject matter experts (SMEs) working directly with the CMO could have prevented this outcome.

Recent enforcement trends highlight the stakes. According to the FDA dashboard database (Ref. 1), Purchasing Controls (21 CFR 820.50) consistently ranks among the top 10 most frequently cited observations in the medical device industry (Figure 1). The rate of citations for purchasing controls rose around 2020 and remains steady at 8%-9% annually (Figure 2). This proves that FDA expects the sponsor to remain accountable for its product even when the production is external. An oversight organization is not a formality, it’s the safeguard that ensures visibility and control across the manufacturing value chain, protects product integrity, and preserves regulatory standing to help avoid costly failures, supply disruptions, or recalls.

From product launches to M&A and manufacturing trends, the MPO Source delivers the medtech news you need twice a week. Subscribe here!

Understanding the Business Model

A foundational step in building an effective oversight organization is understanding the business model governing external manufacturing. Not every CMO requires the same level of involvement, and not every organization welcomes deep process scrutiny. Some CMOs may have proprietary technologies or formulations they are unwilling to fully disclose, while others expect the sponsor to dictate every aspect of production from equipment sourcing to process validation and quality system execution.

Recognizing where each partnership lies on this spectrum is essential. Toll manufacturing, for instance, often demands more technical oversight since the sponsor supplies materials, defines the process, and holds full responsibility for manufacturing controls. Condo or shared-site models, by contrast, rely more on the CMO’s existing systems and infrastructure. Oversight here focuses on governance, segregation, traceability, and data transparency rather than hands-on control.

Sometimes, maintaining an on-site representative such as a quality liaison or process engineer within the CMO’s facility may be necessary to ensure alignment and real-time decision-making. In others, a strong governance framework, periodic audits, and clearly defined communication channels may suffice.

Regardless of the model, one principle remains constant—the sponsor must retain subject matter expertise (SME) over its product and process. The CMO executes the work, but the sponsor owns the process knowledge, the risk decisions, and the ultimate accountability. Allowing a contract manufacturer to independently modify processes or make technical decisions without oversight can lead to compliance gaps, quality failures, or even recalls.

Building a fit-for-purpose oversight organization begins by understanding the nature of the external manufacturing model and tailoring the depth of engagement, control, and technical involvement accordingly.

Designing the Oversight Structure

Once the external manufacturing model is defined, the next step is shaping the oversight organization. Many companies struggle not with documentation or procedures, but with ensuring the right SMEs to review and challenge the work performed by contract manufacturers. Without a defined structure, oversight often becomes fragmented or an afterthought. To address this, most organizations evolve toward one of three governance models (Figure 3): site-integrated oversight, independent virtual plant model, or hybrid—each of which has its own advantages and trade-offs.

• Site-Integrated Oversight Model: In this model, internal manufacturing sites assume responsibility for overseeing CMOs alongside their own production activities. This leverages existing expertise and reduces added overhead, but it also risks uneven oversight, since site teams are typically not incentivized to prioritize external manufacturing needs. Site-integrated oversight offers agility, often at the expense of consistency.
• Independent Virtual Plant Model: A fully dedicated team or “virtual site” is established specifically for contract manufacturing oversight. This group brings together process engineers, automation experts, quality engineers, quality control analysts, regulatory specialists, and sterilization experts, all focused exclusively on external production. Though resource-intensive, this approach provides the strongest compliance posture and the clearest accountability. However, it can be costly and may lack the full product-specific expertise for diverse portfolios (e.g., pharma, device, combination).
• Hybrid Model: The hybrid approach blends both worlds—maintaining a core oversight team while drawing on internal SMEs when specialized expertise is needed. This model balances cost, flexibility, and technical depth.

Key Design Considerations

When choosing a structure, consider where technical expertise resides internally; CMOs’ risk profile; the maturity of existing quality systems; available resources and budget; and decision-making and escalation pathways.

The chosen structure must align with the business strategy and operational reality of the organization. Whether site-integrated, independent virtual site, or hybrid, the mission remains the same—ensuring control, compliance, and collaboration across every external manufacturing partnership.

Building Quality System Elements

Once the oversight structure is defined, the focus shifts to the quality system foundation that governs how external manufacturing will operate. Even the most skilled team cannot succeed without clear processes, defined ownership, and effective supplier performance metrics.

The goal is not to reinvent the quality system, but to extend and adapt it to cover external manufacturing in a consistent and risk-based way. Every core element such as change control, deviations, CAPA, complaint handling, supplier management, and technology transfer should be reviewed through the lens of: What does oversight look like for CMOs, and who is accountable?

1. Quality Agreements: The Governance Backbone – A strong quality agreement is the most important oversight tool. It must go beyond general responsibilities and clearly define how both organizations will collaborate. Ambiguity around ownership of deviations, change controls, or investigations often leads to delays and audit findings. FDA’s “Guidance for Industry: Quality Agreements” says the product owner is ultimately responsible for product quality and compliance, regardless of the manufacturer. Oversight failures often trace back to weak or overly generic agreements. Clarity in the quality agreement prevents confusion during crises.

2. Change Control and Technical Communication – Change control is where many oversight systems fail. CMOs may modify processes, suppliers, or analytical methods without sufficient notification or understanding of product impact. The oversight organization must ensure that all changes are risk-assessed jointly, with defined assessors for each change—process, equipment, analytical, regulatory, or supplier-related. Strong technical communication channels such as monthly meetings, shared dashboards, and escalation protocols can help avoid surprises.

3. Technology Transfer and Knowledge Retention – Incomplete or poorly managed technology transfers can lead to major quality issues. An effective oversight organization ensures that process knowledge is formally documented, transferred, and validated. Using standardized tech transfer templates, joint process verification plans, and pre-transfer readiness assessments significantly reduces startup risk.

4. Supplier Metrics and Ongoing Monitoring – Supplier performance must be measured continuously, not just during audits. Metrics should align with product and supplier criticality, including right-first-time, nonconformance closure time, deviation recurrence rate, complaint rate, and on-time delivery. The most effective programs tier suppliers by risk and tailor oversight frequency accordingly. For example, a high-risk sterile CMO might require quarterly reviews and joint CAPA ownership, whereas a low-risk packaging partner may need only annual business reviews.

5. Audits and Data Transparency – Audits remain a cornerstone of oversight, but they are no longer sufficient on their own. Modern oversight integrates real-time data sharing, trend reports, and remote monitoring tools. Many firms now request access to CMO deviation logs, environmental monitoring data, and CAPA dashboards to identify issues before they escalate. A collaborative, data-driven approach turns oversight into a partnership rather than policing. 

Ongoing Monitoring and Relationship Management

Contract manufacturing oversight doesn’t end once production begins. In fact, that’s when it truly starts. Ongoing monitoring keeps external manufacturing aligned with quality standards, performance expectations, and regulatory responsibilities. Strong oversight programs treat CMOs as extensions of the sponsor’s quality system rather than as independent entities. This requires continuous engagement through structured business reviews, audit programs, performance metrics, and open communication channels.

1. Defining Oversight in Quality and Business Agreements – The quality agreement should clearly outline how ongoing monitoring will occur and who is responsible for each element. Likewise, the business agreement should align operational expectations such as reporting frequency, escalation criteria, and performance targets. Ambiguity in these documents often leads to gaps in follow-up and uneven supplier accountability.

2. Risk-Based Monitoring – Not every CMO requires the same level of oversight. The depth and frequency of monitoring should reflect both the product risk and the supplier performance. For example, a sterile injectable manufacturer producing high-risk combination products may warrant quarterly reviews, frequent audits, and detailed data trending. A packaging CMO with a consistent compliance record may only need annual oversight.

3. Key Oversight Mechanisms – Effective monitoring integrates multiple mechanisms into a cohesive system: supplier scorecards, an audit program, business reviews, and product inspection. While product sampling and inspection can be part of monitoring, sponsors must remember that quality cannot be inspected into a product. True assurance comes from process control and data integrity, not end-stage inspection.

4. Building a Transparent Partnership – The most effective CMO relationships are built on transparency, shared goals, and mutual accountability. Both parties should see oversight not as a policing function but as a partnership aimed at ensuring reliable supply, patient safety, and regulatory compliance. Frequent, open communication supported by data dashboards, monthly meetings, and rapid escalation channels keeps minor deviations from turning into major disruptions. Oversight is not about control; it’s about collaboration with clarity.

Overcoming Common Challenges

Even with the right structure, processes, and agreements in place, contract manufacturing oversight often fails in execution. The reasons are rarely technical and they are almost always rooted in communication, alignment, and process discipline. Understanding these challenges early and addressing them systematically can prevent costly disruptions later in the product lifecycle.

1. Unclear Expectations and Communication Gaps – When expectations are not explicitly defined, both the sponsor and the CMO end up operating under different assumptions. This misalignment can manifest in everything from documentation errors to missed validation steps. Effective oversight requires continuous, structured communication formalized through governance meetings, escalation protocols, and clear decision pathways. Expectations should be defined by the company rather than the CMO.

2. Late Supplier Involvement – A frequent mistake is engaging CMOs too late in the product lifecycle, often after the design or process has been locked. This limits their ability to influence manufacturability and process control, leading to inefficiencies or rework later. Early involvement enables the supplier to understand critical-to-quality (CTQ) attributes, material specifications, and tolerance limits, ensuring that what’s developed in design can be executed on their manufacturing floor without deviation.

3. Overly Complex Processes – Excessively rigid or bureaucratic processes can discourage supplier engagement and slow response times. Oversight must strike a balance between governance and agility. Quality systems should be robust yet practical, ensuring that suppliers can comply without being hindered by administrative burden. The goal is to build systems with CMOs, not for them.

4. Case Example – When CTQs Go Missing. One sponsor developed a new product with a contract manufacturing organization but failed to share its CTQ attributes during the early tech transfer stages. In the absence of clear specifications, the CMO defined their own internal parameters, which did not align with the sponsor’s drawings. As a result, the CTQs were never integrated into the CMO’s in-process inspection plan. This gap was discovered just before product launch forcing a rework of inspection plans, validation protocols, and documentation. The outcome: launch delays, added cost, and strained relationships. In this case, two failures converged—a breakdown in technology transfer and an unclear process validation strategy. Both stemmed from inadequate communication and oversight during setup.

The Path Forward

Successful oversight depends on three factors: clarity, consistency, and collaboration. Expectations must be defined in writing, communicated in real time, and revisited regularly. CMOs should be viewed not as service providers, but as integral partners in the product lifecycle—trusted, empowered, and accountable.

In the end, oversight isn’t about control, it’s about connection. The sponsor may delegate production, but never responsibility. A well-designed oversight organization ensures that every external partnership operates with shared purpose, aligned standards, and unwavering commitment to patient safety and product quality.

Aarti Kamath earned a master’s degree in biomedical engineering from Drexel University. She is a senior quality leader with more than a decade of experience in medical device design, manufacturing and supplier quality. Kamath is an active member of the American Society for Quality and holds certifications in Quality Engineering and Manager of Quality/Organizational Excellence. She currently leads global programs overseeing contract manufacturing and is passionate about advancing quality and innovation across the life sciences industry.